Nanopore Sequencing for RNA Vaccines and Therapeutics:
Advancing Drug Development and Quality Control
About this webinar
Advancements in sequencing technologies are reshaping biopharmaceutical development, with nanopore sequencing emerging as a powerful tool for real-time genetic analysis. While traditionally seen as a niche solution, its unique ability to offer real-time, scalable and portable sequencing has made it a game changer in various fields.
This session will explore how nanopore sequencing is evolving beyond its established applications, including its future role in RNA analysis and its growing adoption in good manufacturing practice (GMP) environments. In this webinar, the expert speakers will discuss how Oxford Nanopore Technologies can complement and enhance traditional analytical methods, offering new opportunities in process development and quality control.
Register for the webinar to gain insights into how nanopore sequencing is poised to become a key player in the biopharma industry and how it can be leveraged in drug development and manufacturing.
Who should attend
- Biopharma and biotech companies
- Regulatory and quality assurance experts
- Academic and industry researchers
What you will learn
- How nanopore sequencing is transforming biopharmaceutical development with real-time genetic analysis
- Its expanding applications beyond traditional uses, including RNA analysis and GMP environments
- Integrating nanopore technology to complement existing analytical methods
- How this technology can optimize processes, accelerate delivery timelines and enhance efficiency in drug development and manufacturing
Featured Speakers
Michaël Lambin
Michaël Lambin is an accomplished leader in biotechnology and pharmaceutical quality management with over 15 years of expertise in analytical method validation, process improvement and team leadership. With a PhD in Molecular Biology, Michael has contributed significantly to scientific research and global QC advancements at GSK, before joining Exothera.
Wei Rong
Wei Rong is a Senior Analytical Scientist with a PhD in Molecular Biology and 13 years of experience in sequencing technologies, including Nanopore, NGS and Sanger. Leading the sequencing platform in both R&D and QC, Wei specializes in Long/short reads sequencing assay development and qualification.
With expertise in Oxford Nanopore Technologies for analytical assay development for both nucleic acid and viral vector projects, NGS-based (illumina) DNA/RNA virus sequencing, and bioinformatics pipeline development, Wei brings a deep understanding of sequencing methodologies in the biopharmaceutical industry.
Olivier Lucas, PhD
Olivier Lucas, PhD, is Director of Biopharma, EMEAI at Oxford Nanopore Technologies. He previously held different clinical and oncology leadership roles at Oxford Nanopore. He has a background in molecular biology and has been in the genomics industry for over 12 years.
Partner for this event
Exothera
Exothera is a specialized CDMO partner delivering preclinical and clinical process development, manufacturing optimization and CMC support for virus- and RNA-based therapeutics and vaccines.
We assist clients from start to scale, up to commercial manufacturing, including analytical testing and regulatory consultation. Thanks to our optimal technologies and experienced team, we help bring innovative therapies from bench to patient with quality, at speed and cost-effectiveness.